Last Updated : April 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area Sort descending | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Mictoryl | Propiverine hydrochloride | Overactive bladder (OAB) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Ralivia | Tramadol hydrochloride | Pain | Do not list | Complete | ||
| Tridural | Tramadol hydrochloride | Pain | Do not list | Complete | ||
| Fentora | Fentanyl buccal | Pain (breakthrough), cancer (adults) | Do not reimburse | Complete | ||
| Zytram XL | Tramadol hydrochloride | Pain, acute | Withdrawn | |||
| Zytram XL | Tramadol hydrochloride | Pain, acute | Do not list | Complete | ||
| Abstral | Fentanyl citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Do not list | Complete | ||
| Onsolis | Fentanyl Citrate | Pain, breakthrough cancer pain | Withdrawn | |||
| Sativex | Delta-9-tetrahydrocannabinol/cannabidiol | Pain, cancer (adjunctive analgesia to maximum tolerated strong opioids) | Do not list | Complete |
Last Updated : April 28, 2024